Röchling Medical and Trendlines Innovation Labs Join Forces to Offer Top Innovation and Manufacturing Expertise to the Healthcare Industry
Röchling Medical, a division of the German-based Röchling Group and a leading manufacturer for the healthcare industry, and Trendlines Innovation Labs, the innovation and R&D arm of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), announced a collaboration agreement to provide a one-stop-shop for medical device innovation, development, and manufacturing.
Röchling Medical is a renowned partner to leading pharmaceutical, biotech and medtech companies worldwide, offering complete manufacturing solutions and a wide range of high-quality, customized components and assemblies, including end-to-end OEM products. Röchling Medical brings a proven track record of serving the life science and pharmaceutical industry. As a manufacturing partner, Röchling Medical offers flexibility, responsiveness, and traceability – from start to finish.
Trendlines Innovation Labs is an innovation partner, inventing and investing with life science companies. Trendlines Innovation Labs brings a wealth of expertise in invention and R&D of breakthrough medical products with a focus on early-stage development. Trendlines Innovation Labs’ strength is its ability to invent new solutions and products with speed and focus, that meet critical unmet needs with an aim to improve the human condition.
The collaboration agreement leverages on the strengths of each party and on the grounds that by joining forces, the parties will expand and enhance the value proposition and offering of complete innovation, product development and manufacturing solutions to the healthcare industry, broadening their individual and joint endeavors.
Dr. Boris Fröhlich, President & CEO of Röchling Medical, commented: “We are enthusiastic about working together with Trendlines Innovation Labs. This collaboration addresses our partners’ needs to the fullest extent. We are amazed that we have entered into this great partnership to support our partners in providing health to the people around the globe.”
Nir Goldenberg, CEO of Trendlines Innovation Labs, added, “We are extremely excited about our collaboration with Röchling Medical. By joining forces we’ll be able to provide a greater value proposition for our partners, together with timely and quality delivery of product innovation, development, and manufacturing. By working together, we’ll significantly enhance our joint proposition, together with the product offering of our partners.”
- Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Read more
- iCRYO Announces Partnership with Therapeutic Manufacturer, BTL Read more
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis Read more
- Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease Read more
- Poseida Therapeutics Announces Board Change Read more